tweenvest

Beijing Luzhu Biotechnology Co., Ltd. (SEHK: 2480)

Salud · Biotecnología · CN

15,30 HK$

0,00 % hoy · -29,8 % 1 año

Ficha pública
Un resumen gratuito de Beijing Luzhu Biotechnology Co., Ltd., con datos del 15 nov 2026. El análisis completo está en la app.Abrir en la app

Beijing Luzhu Biotechnology Co., Ltd. (SEHK: 2480) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 387,91 M $ y tiene 193 empleados.

En los últimos doce meses la acción ha bajado un 29,8 % y ha cotizado entre 12,00 y 25,98.

Tweenvest puntúa a Beijing Luzhu Biotechnology Co., Ltd. en cuatro factores: calidad 50/100, valor 64/100. Su punto más fuerte es valor.

Evolución de la cotización de 2480

21 nov 2025 · 21,06Cierres semanales 12,35 – 25,8613 nov 2026 · 15,30

Cifras clave

Capitalización
387,91 M $
Ingresos (últ. 12 m)
—
PER
-20,13
BPA
-0,78
Rent. por dividendo
—
Beta (5 años)
-0,66
Máximo 52 semanas
25,98 HK$
Mínimo 52 semanas
12,00 HK$
Volumen medio (3 m)
—
Acciones en circulación
198,91 M
Empleados
193
Próximos resultados
—

Sobre Beijing Luzhu Biotechnology Co., Ltd.

Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China. The company is developing LZ901, a recombinant herpes zoster vaccine for which a biologics license application (BLA) has been submitted; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection that has completed a Phase 1 clinical trial for the treatment of autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis; and K193, a bispecific antibody injection in a Phase 1 clinical trial for the treatment of B cell leukemia and lymphoma. Its preclinical-stage product candidates comprise a recombinant varicella vaccine for the prevention of varicella in children; a recombinant syncytial virus (RSV) vaccine for RSV-induced lower respiratory tract disease; a recombinant HSV-1 vaccine that targets oral herpes or cold sores; a recombinant HSV-2 vaccine that targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932, a bispecific antibody to treat b cell lymphoma. In addition, the company offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and Haemophilus influenzae Type B polysaccharide IgG antibody detection kits; varicella-zoster virus antibody ELISA testing kits; and varicella-zoster virus antigen slides. Beijing Luzhu Biotechnology Co., Ltd. was incorporated in 2001 and is headquartered in Beijing, China.

ISIN
CNE100005YD8
Fundada en
2001
Cotiza desde
8 may 2023
Bolsa
The Stock Exchange of Hong Kong Ltd.
Divisa
HKD
EmpresaCapitalizaciónPrecioDía
SanBio Company LimitedTSE: 4592395,95 M $808,00 ¥0,00 %
Edding Genor Group Holdings LimitedSEHK: 6998394,79 M $1,55 HK$+1,97 %
Pharmicell Co., Ltd.KOSE: A005690389,17 M $8670,00 ₩+1,05 %
Landfar Bio-medicine Co., LtdSZSE: 000504388,11 M $7,85 CN¥-4,96 %
Shanghai Kehua Bio-Engineering Co.,LtdSZSE: 002022387,49 M $4,99 CN¥-1,96 %
Avalo Therapeutics, Inc.NasdaqCM: AVTX387,41 M $6,70 $-6,03 %
Beijing Kawin Technology Share-Holding Co., Ltd.SHSE: 688687386,54 M $15,41 CN¥-1,85 %
Opus Genetics, Inc.NasdaqCM: IRD384,68 M $3,98 $-1,97 %

Ver todas las empresas de biotecnología →